Cargando…

Exogenous melatonin as potential adjuvant in anti-SarsCov2 vaccines

Detalles Bibliográficos
Autor principal:	Maestroni, Georges
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481341/ https://www.ncbi.nlm.nih.gov/pubmed/32910359 http://dx.doi.org/10.1007/s11481-020-09956-1

Ejemplares similares

Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients
por: DUCLOUX, Didier, et al.
Publicado: (2022)

Is SARSCoV-2 nasopharyngeal swab still a gold standard in children?
por: Marino, Silvia, et al.
Publicado: (2020)

Nephrotic Syndrome Following ChAdOx1 nCoV-19 Vaccine Against SARScoV-2
por: Anupama, Y.J., et al.
Publicado: (2021)

(590) Sars_Cov2 Experience in the West Australian Heart Transplant Population
por: House, C., et al.
Publicado: (2023)

Melatonin: Revisited Role as Vaccine Adjuvant During Outbreaks of COVID-19 Caused by the Delta Variant
por: Kow, Chia Siang, et al.
Publicado: (2021)

High seroprevalence of SARS_COV-2 in Bergamo: evidence for herd immunity or reason to be cautious?
por: Signorelli, Carlo, et al.
Publicado: (2020)

There is an urgent need for safer anti-SARS-CoV-2 vaccines
por: Finsterer, Josef
Publicado: (2022)

Gastrointestinal tract diseases as a risk factor for SARSCoV2 rectal shedding? An Italian report on 10 COVID-19 patients
por: Patrì, Angela, et al.
Publicado: (2021)

SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab
por: Khayat-Khoei, Mahsa, et al.
Publicado: (2021)

Granulomatous vasculitis after the AstraZeneca anti–SARS-CoV-2 vaccine
por: Gillion, Valentine, et al.
Publicado: (2021)

Impact of therapeutic plasma exchange on acquired vaccinal anti-SARS-CoV-2 antibodies
por: Lambert, Catherine, et al.
Publicado: (2022)

Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases
por: Manolache, Narcis-George, et al.
Publicado: (2022)

SARSCOV-2 vaccine associated with primary cutaneous peripheral T cell lymphoma
por: Montoya, VH Garcia, et al.
Publicado: (2022)

Leukocytoclastic Vasculitis and SARS-COV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Esophagitis and SARS-CoV-2 vaccine
por: Sriwijitalai, Won, et al.
Publicado: (2023)

A mouse model for SARS-CoV-2 infection by exogenous delivery of hACE2 using alphavirus replicon particles
por: Zhang, Ya-Nan, et al.
Publicado: (2020)

Humoral and T cell Responses to SARS-CoV-2 Vaccine Booster and Anti-SARS-CoV-2 Monoclonal Antibodies in Patients With End-Stage Kidney Disease
por: Zaza, Gianluigi, et al.
Publicado: (2023)

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
por: Salvagno, G.L., et al.
Publicado: (2022)

Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2
por: Haskologlu, Ismail Celil, et al.
Publicado: (2022)

Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2
por: Lei, Hong, et al.
Publicado: (2020)

SARS-CoV-2 and the myths about vaccination()
por: Travezaño-Cabrera, Aaron, et al.
Publicado: (2021)

Immunophenotyping of SARS-CoV-2 and vaccine design
por: Cimolai, Nevio
Publicado: (2022)

Esophagitis and SARS-CoV-2 vaccine: Correspondence
por: Sriwijitalai, Won, et al.
Publicado: (2023)

Comment on the effectiveness of four SARS-COV-2 vaccines
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

The statistical risk of diagnosing coincidental acquired hemophilia A following anti‐SARS‐CoV‐2 vaccination
por: Cittone, Micol G., et al.
Publicado: (2021)

ANCA-associated Vasculitic Neuropathy Following Anti-SARS-CoV-2 Vaccination: An Epiphenomenon or Causal Association?
por: Jha, Shreyashi, et al.
Publicado: (2023)

The need to shed light on potential insidious SARS-CoV-2 post-vaccination pituitary lesions
por: Ach, Taieb, et al.
Publicado: (2022)

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
por: Barrière, J., et al.
Publicado: (2021)

Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination
por: Sacker, Allan, et al.
Publicado: (2021)

Reply: Subacute thyroiditis after anti-SARS-CoV-2 (Ad5-nCoV) vaccine()
por: Flores-Rebollar, Armando
Publicado: (2022)

Passive inhaled mRNA vaccination for SARS-Cov-2
por: Yeo, Wee Song, et al.
Publicado: (2021)

Commentary: SARS-CoV-2 vaccines and cancer patients
por: Corti, C., et al.
Publicado: (2021)

Impact of SARS-CoV-2 vaccines on the nervous system
por: Scorza, Fulvio Alexandre, et al.
Publicado: (2022)

Graves’ disease following SARS-CoV-2 vaccination
por: Sriphrapradang, Chutintorn, et al.
Publicado: (2021)

Vaccination of susceptible animals against SARS-CoV-2
por: Xiang, Bin, et al.
Publicado: (2022)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

SARS‐CoV‐2 vaccinations can trigger polyradiculitis
por: Finsterer, Josef, et al.
Publicado: (2022)

Subacute thyroiditis and different SARS-CoV-2 vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_380915ij13nj58sulnbls58p19